- Home
- SMHI vs CRDL Comparison
SMHI vs CRDL Comparison
Compare SMHI & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMHI
- CRDL
- Stock Information
- Founded
- SMHI 1989
- CRDL 2017
- Country
- SMHI United States
- CRDL Canada
- Employees
- SMHI N/A
- CRDL N/A
- Industry
- SMHI Marine Transportation
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SMHI Consumer Discretionary
- CRDL Health Care
- Exchange
- SMHI Nasdaq
- CRDL Nasdaq
- Market Cap
- SMHI 139.9M
- CRDL 112.4M
- IPO Year
- SMHI N/A
- CRDL N/A
- Fundamental
- Price
- SMHI $5.87
- CRDL $1.30
- Analyst Decision
- SMHI
- CRDL Strong Buy
- Analyst Count
- SMHI 0
- CRDL 2
- Target Price
- SMHI N/A
- CRDL $9.00
- AVG Volume (30 Days)
- SMHI 127.5K
- CRDL 205.8K
- Earning Date
- SMHI 07-30-2025
- CRDL 08-11-2025
- Dividend Yield
- SMHI N/A
- CRDL N/A
- EPS Growth
- SMHI N/A
- CRDL N/A
- EPS
- SMHI N/A
- CRDL N/A
- Revenue
- SMHI $264,089,999.00
- CRDL N/A
- Revenue This Year
- SMHI N/A
- CRDL N/A
- Revenue Next Year
- SMHI $11.59
- CRDL N/A
- P/E Ratio
- SMHI N/A
- CRDL N/A
- Revenue Growth
- SMHI N/A
- CRDL N/A
- 52 Week Low
- SMHI $3.63
- CRDL $0.77
- 52 Week High
- SMHI $15.36
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- SMHI 53.17
- CRDL 47.68
- Support Level
- SMHI $5.38
- CRDL $1.22
- Resistance Level
- SMHI $5.79
- CRDL $1.54
- Average True Range (ATR)
- SMHI 0.28
- CRDL 0.10
- MACD
- SMHI -0.01
- CRDL -0.01
- Stochastic Oscillator
- SMHI 67.39
- CRDL 28.33
About SMHI SEACOR Marine Holdings Inc.
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.